Sequent
Proven Ability In Life Sciences

December 11, 2019

To,

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001

Scrip code: 512529

National Stock Exchange of India Limited
Listing Department
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Compliance under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transactions on a consolidated basis for the half year ended September 30, 2019, in the format specified in the relevant Accounting Standards.

You are requested to take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited

SEQUENT SCIENTIFIC LTD.

Krunal Shah
Company Secretary & Compliance Officer
Encl: as above

Disclsoure of related party transactions on consolidated basis

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

A List of related parties

a) Key management personnel

Mr. Manish Gupta, Chief Executive Officer & Managing Director
Mr. Sharat Narasapur, Joint Managing Director
Mr. Tushar Mistry, Chief Financial Officer
Mr. Krupesh Mehta, Company Secretary (Till 29th June, 2019)
Mr. Krunal Shah, Company Secretary (From 13th November, 2019)
Mr. K E C Rajakumar, Non-Executive Director
Dr. S Devendra, Non-Executive Director
Dr. Gopakumar G. Nair, Chairman and Independent Director
Dr Kausalya Santhanam, Independent Director
Mr. Narendra Mairpady, Independent Director

b) Enterprises owned or significantly influenced by individuals who have control/significant influence over the Company/ subsidiaries

Strides Pharma Sciences Limited
Strides Emerging Markets Limited
Solara Active Pharma Sciences Limited
Sequent Penems Private Limited
Naari Pharma Private Limited
Tenshi Kaizen Private Limited

SEQUENT SCIENTIFIC LTD.

B · Transactions during the period 1st April, 2019 to 30th September, 2019

(₹ in Million)

Particulars	Key management personnel	Enterprises owned or significantly influenced by individuals who have control/ significant influence over the Company / subsidiaries
Sale of materials/services		
Strides Pharma Sciences Limited		0.13
Strides Emerging Markets Limited		0.01
Solara Active Pharma Sciences Limited		155.62
Tenshi Kaizen Private Limited		0.06
Purchase of materials		
Solara Active Pharma Sciences Limited		47.37
Strides Pharma Sciences Limited		-
Managerial remuneration		
Mr. Manish Gupta	25.26	
Mr. Sharat Narsapur	4.60	
Mr. Tushar Mistry	4.22	
Mr. Krupesh Mehta	0.39	
Directors Sitting Fees	1.32	
Reimbursement of expenses from		
Solara Active Pharma Sciences Limited		0.92
Commission expense		
Solara Active Pharma Sciences Limited		0.41
Rent expense		
Solara Active Pharma Sciences Limited		4.20
Sequent Penems Private Limited		1.27

C Balance as at 30th September, 2019

(₹ in Million)

Trade Receivables / other current assets		
Strides Emerging Markets Limited		0.01
Naari Pharma Private Limited		8.93
Solara Active Pharma Sciences Limited		108.39
Tenshi Kaizen Private Limited		0.03
Security deposit receivable		
Solara Active Pharma Sciences Limited		4.20
Sequent Penems Private Limited		2.50
Trade payables		
Solara Active Pharma Sciences Limited		13.17

For Sequent Scientific Limited

SEQUENT SCIENTIFIC LTD.

Tushar Mistry
Chief Financial Officer

Krunal Shah
Company Secretary & Compliance Officer